Targovax ASA logo

TRVX - Targovax ASA News Story

NOK8.05 0.4  4.6%

Last Trade - 3:25pm

Sector
Healthcare
Size
Micro Cap
Market Cap £49.3m
Enterprise Value £46.2m
Revenue £238k
Position in Universe 989th / 1784

BRIEF-Targovax: one-year survival rate and safety data in modified cohort of TG01 trial in resected pancreatic cancer

Thu 12th October, 2017 6:00am
Oct 12 (Reuters) - TARGOVAX ASA  TRVX.OL : 
    * ANNOUNCES ONE-YEAR DATA ON SURVIVAL RATE, IMMUNE 
ACTIVATION AND SAFETY IN MODIFIED COHORT OF TG01 TRIAL IN 
RESECTED PANCREATIC CANCER PATIENTS. 
 
Source text for Eikon:  ID:nGNE1SYPZp  
Further company coverage:  TRVX.OL  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.